Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Commercial Product, Through US Retail Pharmacies
Benzinga Newsdesk 9 months ago
BiotechHealth CareGeneral
CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a rapid commercialization
CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a rapid commercialization plan is underway with a national sales force to be deployed in mid-February 2026.